BeiGene files patent suits against Sandoz, MSN Group

BeiGene celebrated its fifth indication for Brukinsa with a lawsuit.

A day after winning an accelerated approval in follicular lymphoma, BeiGene filed complaints against Sandoz and subsidiaries of MSN Group over applications to market generic versions of Brukinsa. The company claims that Sandoz and MSN infringed patents on the blood cancer blockbuster and has asked the court to bar Sandoz and MSN from commercializing their generics until the patents expire.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Sanofi scoops up U.S. biotech Inhibrx for up to $2.2 billion as it seeks to bolster pipeline

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up

January 23, 2024

Inpatient costs of treating COVID-19 in the U.S.

Study analyzes the average inpatient care costs for COVID-19 patients, revealing significant variations in expenses across pandemic waves and patient demographics.

January 8, 2024

Lung cancer screening with CT can identify coronary artery calcium

Lung cancer screening with low-dose chest computed tomography (CT) may detect more than just lung cancer. As new research in CMAJ (Canadian Medical Association Journal)

December 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.